Pulmonary Synovial Sarcoma: A Rare Lung Cancer Explained
"A deep dive into a rare case of primary synovial sarcoma of the lung, its diagnosis, and treatment approaches."
Primary synovial sarcoma of the lung is an exceptionally rare cancer. This article explores a unique case where a previously healthy 47-year-old male presented with a short history of dyspnea. This case highlights the challenges in diagnosing and treating such an uncommon condition.
The patient's symptoms included increasing shortness of breath, left-sided chest pressure, diminished appetite, and unexplained weight loss over three months. Initial chest X-rays revealed a large mass-like density in the left upper lobe, prompting further investigation.
Subsequent CT scans confirmed a significant, heterogeneously enhancing mass in the left hemithorax, measuring 16 x 14 x 16 cm. The mass exhibited neovascularity and focal calcifications, causing mediastinal shift and compression atelectasis. A smaller, separate mass was also identified in the left lung apex. To determine next steps, core biopsies were obtained.
A Rare Lung Cancer
Pulmonary synovial sarcoma is a rare form of lung cancer, so its true frequency and population-level impact are difficult to define precisely. Available evidence largely comes from case reports, case series, and retrospective studies rather than large prospective trials. This limited evidence base makes prognosis and treatment comparisons difficult.
Treatment Remains Individualized
There is no standardized therapy or specific guideline for primary pulmonary synovial sarcoma. Complete surgical resection is the only approach consistently associated with survival in the cited literature, but one review reports that only about one third of tumors are resectable at presentation. Surgery is commonly combined with neoadjuvant or adjuvant chemotherapy and radiotherapy; one 2026 case involving borderline pulmonary function used neoadjuvant Adriamycin, Ifosfamide, and Mesna after referral to a sarcoma specialty center.
Evidence Built Through Case Reports
The medical understanding of primary pulmonary synovial sarcoma has developed mainly through individual cases and small series because the tumor is extremely uncommon. Reports include a 2018 case involving a previously healthy patient with a short course of dyspnea and a large lung tumor, a 2022 case series of three histologically confirmed cases with predominantly pulmonary involvement, and a 2023 report describing long-term survival after complete resection and multimodal treatment. A separate report presented two cases and emphasized that primary synovial sarcoma is uncommon in the lung, while sarcomas overall account for only 0.1–0.5% of lung cases.
Decoding the Diagnosis: From Biopsy to Molecular Confirmation
Pathological examination of the biopsy samples revealed a spindle cell neoplasm consistent with synovial sarcoma. Immunohistochemical staining showed a monomorphous spindle cell proliferation positive for TLE-1. Crucially, Cytokeratin, S-100, TTF-1, desmin CD 117, and CD 34 markers were negative, further narrowing the diagnosis.
- TLE-1 Positive: Indicates the presence of this marker, commonly found in synovial sarcomas.
- Cytokeratin, S-100, TTF-1, desmin CD 117, and CD 34 Negative: Rules out other potential types of tumors.
- SYT Gene Rearrangement Positive: Confirms the characteristic genetic abnormality in synovial sarcoma.
Research Is Expanding
A Mayo Clinic study reviewed patients treated for primary thoracic synovial sarcoma between 1994 and 2022, excluding thoracic spine involvement, and examined demographics, tumor characteristics, treatments, and outcomes. Recent reporting also highlights that primary pulmonary synovial sarcoma can be difficult to diagnose because its presentation is nonspecific and its imaging may overlap with other thoracic malignancies. At the molecular level, a 2025 review described significant progress over the preceding five years in understanding synovial sarcoma's molecular, genomic, and epigenetic mechanisms.
Limits of the Evidence
The evidence does not support a simple, uniformly effective treatment pathway for primary pulmonary synovial sarcoma. The condition is extremely rare, and one study specifically sought to identify which clinicopathologic and therapeutic factors determine survival, underscoring that these relationships remain uncertain. Case-based evidence also shows that patients may present with a large tumor after only a short course of dyspnea, illustrating why diagnosis and treatment can be challenging.
Primary Versus Metastatic Disease
Comparative analysis must distinguish a synovial sarcoma that originates in the lung from one that spreads there from another site. A study evaluated the clinical, radiological, and pathological findings in 60 cases of primary pulmonary and mediastinal synovial sarcoma and compared them with five prior large series. In contrast, a 2025 case report described pulmonary metastasis after surgery for synovial sarcoma originating in the sole of the foot, showing why the tumor's site of origin matters when interpreting lung involvement.
Treatment Strategies and Prognosis: Navigating the Challenges
Given the complexity of the case, the patient's treatment plan was developed by the thoracic oncology tumor board. The initial approach involved neoadjuvant chemotherapy with epirubicin and ifosfamide, aimed at reducing the tumor size prior to surgical intervention.
Multimodal Care, Limited Certainty
Primary thoracic synovial sarcoma is a rare and aggressive malignancy for which treatment-outcome data remain limited. Institutional and retrospective studies are being used to examine clinicopathologic features, treatment choices, and survival because prospective evidence is scarce. Individual reports nevertheless describe long-term survival after complete resection followed by a multimodal approach, supporting the importance of individualized management at experienced centers.
Toward Better Evidence
Future progress will depend on improving evidence for a cancer that accounts for less than 0.5% of all primary lung malignancies, according to the cited material. Recent work is examining primary thoracic synovial sarcoma across long treatment periods, including Mayo Clinic patients treated from 1994 through 2022, while molecular and epigenetic research is clarifying the biology of synovial sarcoma. These efforts may help refine diagnosis, risk assessment, and treatment selection, although the available sources do not establish a specific future therapy.
Rarity Creates Diagnostic Barriers
Primary pulmonary synovial sarcoma accounts for less than 0.5% of all primary lung malignancies in the cited report. Unlike other primary lung malignancies, it has no known association with tobacco exposure or environmental carcinogens. Its etiology, imaging features, and optimal treatment are not well understood, and rare complications reported in the literature include pulmonary pseudoaneurysms and lymphadenopathy.
An Uncertain Patient Journey
For patients, pulmonary synovial sarcoma can involve uncertainty because symptoms may be nonspecific and the diagnosis is uncommon. The available case material describes people presenting with shortness of breath or facing treatment decisions shaped by factors such as pulmonary function and access to specialty care. Outcomes can vary, and published cases cannot by themselves predict what will happen for an individual.
The plan included a subsequent thoracotomy and resection if feasible. The patient tolerated the first cycle of chemotherapy well.
It's important to acknowledge that the overall five-year survival rate for pulmonary synovial sarcoma remains below 50%. Factors such as tumor size (>5 cm), higher grade, male sex, older age, neurovascular invasion, and specific genetic variants (SYT-SSX1) are associated with poorer prognoses. Due to size, surgical resection is often not possible upfront and neo-adjuvant chemotherapy is given.